Health panel approves coverage for iPS cell-derived Parkinson’s disease treatment ^37.1%

The Japan Times - By Jessica Speed - 5/13/2026, 9:00 AM

Unattributed Quote 50% - Halo Effect 39.8% - Primacy Effect 39.8%

An advisory panel to the health minister on Wednesday approved Sumitomo Pharma’s Parkinson’s disease treatment Amchepry, which costs ¥55.3 million ($350,600) per patient, to be covered under the national healthcare program. The approval marks the first commercialized medical product in the world derived from iPS cells, which are created... more